Randomized, Active-controlled, Parallel Group, 16-Week Open Label Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo (Insulin Glargine-U300) Versus Lantus in Patients With Type 1 Diabetes Mellitus
Phase of Trial: Phase IV
Latest Information Update: 27 Jun 2017
At a glance
- Drugs Insulin glargine (Primary)
- Indications Type 1 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Sanofi
- 21 Jun 2017 Status changed from active, no longer recruiting to completed.
- 20 Feb 2017 Status changed from recruiting to active, no longer recruiting.
- 14 Dec 2016 Planned End Date changed from 1 Apr 2017 to 1 Jun 2017.